with noncancer pain and OIC (KODIAC-04, n=652 [NCT01309841 ] ; KODIAC-05, n=700 [NCT01323790 ] ), we compared the effect of daily oral administration of naloxegol 12.5 or 25 mg vs placebo on signs and symptoms of OIC in the intent-to-treat population over 12 weeks of treatment. ...